55

Literatur

1. Bamberg M, Schmoll HJ, Weissbach L, Beyer J, Bokemeyer C, Harstrick A, Höltl W, Souchon R, Vogler H (1997 ): "Interdisziplinäre Konsensus-Konferenz zur "Diagnostik und Therapie von Hodentumoren"." Strahlenther Onkol 173 :397-406 .

2. Beyer J, Grabbe J, Lenz K, Weisbach V, Strohscheer I, Huhn D, Siegert W (1992 ): "Cutaneous toxicity of high-dose carboplatin, etoposide and ifosfamide followed by autologous stem cell reinfusion." Bone Marrow Transplant 10 :491-494 .

3. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1994 ): " Treatment intensification in disseminated germ-cell tumors." World J Urol 12 :207-213 .

4. Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, Oettle H, Serke S, Huhn D, Siegert W (1995 ): "Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison." J Clin Oncol 13 :1328-1335 .

5. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1996 ): " Hochdosischemotherapie bei Hodentumoren." Onkologe 2 :S28-S32 .

6. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1996 ): " High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic factors." J Clin Oncol 14 :2638-2645 .

7. Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, Huhn D, Siegert W (1997 ): "Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy." Cancer 79 :161-168 .

8. Beyer J, Rick O, Weinknecht S, Kingreen D, Lenz K, Siegert W (1997 ): " Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome." Bone Marrow Transplant 20 :813-819 .

9. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1998 ): " Salvagetherapie rezidivierter und refraktärer Hodentumoren." Onkologe 4 :541-546 .

10. Beyer J, Schmoll HJ (1998 ): "Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumoren." Onkologe 4 :518-523 .

11. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W (1999 ): " High-dose versus conventional-dose first-salvage treatment in nonseminoma: a matched-pair analysis." Proc Am Soc Clin Oncol 19 :1255 .

12. Blijham G, Spitzer G, Litam J, Zander AR, Verma DS, Vellekoop L, Samuels ML, McCredie KB, Dicke KA (1981 ): "The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support" . Eur J Cancer 17 :433-441 .

56

13. Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W (1995 ): " Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer" . J Natl Cancer Inst 87 :58-60 .

14. Bosl GJ, Yagoda A, Golbey RB, Whitmore Jr. W, Herr H, Sogani P, Morse M, Vogelzang N, MacDonald G (1985 ): "Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors." Am J Med 78 :423-428 .

15. Bosl G, Motzer RJ (1997 ): "Testicular germ-cell cancer" . N Engl J Med 337 :242-253 .

16. Broun ER, Nichols CR, Einhorn LH, Tricot GJK (1991 ): "Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors" . Cancer 68 :1513-1515 .

17. Broun ER, Nichols CR, Tricot G, Loehrer PJ, Williams SD, Einhorn LH (1991 ): "High-dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors." Bone Marrow Transplant 7 :53-56 .

18. Broun ER, Nichols CR, Kneebone P, Williams SD, Loehrer PA, Einhorn LH, Tricot G (1992 ): "Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue." Ann Intern Med 117 :124-128 .

19. Broun ER, Nichols CR, Turns M, Williams SD, Loehrer PJ, Roth BJ, Lazarus HM, Einhorn LH (1994 ): "Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support." Cancer 73 :1716-1720 .

20. Broun ER, Nichols CR, Mandanas R, Salzman D, Turns M, Hromas R, Cornetta K, Einhorn LH (1995 ): "Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors." Bone Marrow Transplant 16 :353-358 .

21. Cockroft DW, Gault MH (1976 ): " Prediction of creatinine clearance from serum creatinine." Nephron 16 :31-41 .

22. Cox DR (1972 ): "Regression models and life-tables." J R Stat Soc (B) 34 :187-220 .

23. Dieckmann KP, Kreuser ED (1991 ): " Aktueller Stand der Chemotherapie von Keimzelltumoren." Urologe A 30 :45-54 .

24. Einhorn LH (1990 ): "Treatment of testicular cancer: a new and improved model." J Clin Oncol 8 :1777-1781 .

25. Farhat F, Culine S, Theodore C, Bekradda M, Terrier-Lacombe MJ, Droz JP (1996 ): "Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients." Cancer 77 :1193-1197 .

57

26. Fields K, Elfenbein GJ, Lazarus H, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE (1995 ): "Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile." J Clin Oncol 13 :323-332 .

27. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJS, Cook PA (1999 ): "Prognostic factors in patients relapsing after platinum-based chemotherapy for malignant non-seminomatous germ cell tumours." Br J Cancer :in press.

28. Gale RP, Henon P, Huttner C (1992 ): "Blood stem cell transplantation come of age." Bone Marrow Transplant 9 :151-155 .

29. Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W (1995 ): "Prognosis after salvage treatment for unselected male patients with germ cell tumours." Br J Cancer 72 :1026-1032 .

30. Goodnough L, Brecher ME, Kanter MH, AuBuchon JP (1999 ): "Transfusion medicine." N Engl J Med 340 :438-447 .

31. Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, Kovnar EH (1987 ): "Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy." Cancer Res 47 :1457-1460 .

32. Gulati SC (1994 ): "Did we focus on the most important issues in the use of growth factors and stem-cell transplantation." J Clin Oncol 12 :650-652 .

33. Hainsworth JD, Williams SD, Einhorn LE, Birch R, Greco FA (1985 ): " Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group Trial." J Clin Oncol 3 :666-671 .

34. Harding MJ, Paul J, Gillis CR, Kaye SB (1993 ): " Management of malignant teratoma: does referral to a specialist unit matter?" Lancet 341 :999-1002 .

35. Harstrick A, Schmoll HJ, Wilke H, Köhne-Wömpner CH, Stahl M, Schöber C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, Bergmann L, Lammers U, Freund M, Poliwoda H (1991 ): "Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma." J Clin Oncol 9 :1549-1555 .

36. Hildebrandt MO, Blaser F, Beyer J, Siegert W, Mapara MY, Huhn D, Salama A (1998 ): "Detection of tumor cells in peripheral blood samples from patients with germ cell tumors using immunocytochemical and reverse transcriptase_polymerase chain reaction techniques." Bone Marrow Transplant 22 :771-775 .

37. Hölzel D, Altwein JE (1991 ): "Hodentumoren. Ist der Rückgang der Mortalität in der Bundesrepublik Deutschland zu langsam erfolgt?" Deutsch Ärztebl 88 :B2694-B2700 .

58

38. Hölzel D, Klamert A, Schmidt M. Krebs . Häufigkeiten, Befunde und Behandlungsergebnisse. München : Zuckschwerdt Verlag , 1996 .

39. Horwich A (1995 ): "Salvage therapy of germ cell tumours." Br J Cancer 71 :901-903 .

40. ICH. Harmonised tripartite guideline for good clinical practice. Richmond, Surrey, UK : Brookwood Medical Publications Ltd , 1997 .

41. International Germ Cell Cancer Collaborative Group (1997 ): " International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers." J Clin Oncol 15 :594-603 .

42. Josefsen D, Ous S, Hoie J, Stenwig AE, Fossa SD (1993 ): " Salvage treatment in male patients with germ cell tumours." Br J Cancer 67 :568-572 .

43. Kaplan EL, Meier P (1958 ): " Non-parametric estimation from incomplete observations." J Am Stat Assoc 53 :457-481 .

44. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948 ): " The use of the nitrogen mustards in the palliative treatment of carcinoma." Cancer 1 :634-656 .

45. Kessinger A, Armitage JO (1991 ): "The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies." Blood 77 :211-213 .

46. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS (1995 ): "Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial" . J Clin Oncol 13 :1323-1327 .

47. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Harmtmann JT, Biron P, Fléchon A, Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C (1998 ): "Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. " J Clin Oncol 16 :3386-3391 .

48. Lampe H, Dearnaley D, Price A, Mehta J, Powles R, Nicholls J, Horwich A (1995 ): "High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours." Eur J Cancer 31A :717-723 .

49. Ledermann JA, Holden L, Newlands ES, Begent RHJ, Rustin GJS, Bagshawe KD, Brampton M (1994 ): "The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours." Br J Urol 74 :225-230 .

50. Levine EG, Raghavan D (1991 ): "Treatment of refractory testis cancer: salvage or savage chemotherapy?" Eur J Cancer 27 :932-936 .

51. Linkesch W, Krainer M, Wagner A (1992 ): " Phase I/II trial of ultrahigh dose carboplatin, etoposide, cyclophosphamide with ABMT in refractory nonseminomatous germ cell tumors (GCT)." Proc Am Soc Clin Oncol 11 :196 (abstract 600).

59

52. Loehrer PJ, Einhorn LH, Williams SD (1986 ): "VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer." J Clin Oncol 4 :528-536 .

53. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998 ): "Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor." J Clin Oncol 16 :2500-2504 .

54. Mantel N (1966 ): " Evaluation of survival data and two new rank order statistics arising in its consideration." Cancer Treat Rep 50 :163-170 .

55. McCaffrey JA, Mazumdar M, Bajorin D, Bosl GJ, Vlamis V, Motzer RJ (1997 ): "Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival." J Clin Oncol 15 :2559-2563 .

56. Morrow GR, Hickok JT, Rosenthal SN (1995 ): "Progress in reducing nausea and emesis." Cancer 76 :343-357 .

57. Motzer RJ, Cooper K, Geller NL, Bajorin DF, Dmitrovsky E, Herr H, Morse M, Fair W, Sogani P, Russo P, Bosl GJ (1990 ): "The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors." Cancer 66 :2476-2481 .

58. Motzer RJ, Gulati SC, Crown JP, Weisen S, Doherty M, Herr H, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl G J (1992 ): "High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors: Early intervention is better tolerated." Cancer 69 :550-556 .

59. Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V (1996 ): "High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity." J Clin Oncol 14 :1098-1105 .

60. Mulder POM, De Vries EGE, Schraffordt Koops H, Splinter TED, Maas A, Van der Geest S, Mulder NH, Sleijfer DTH (1988 ): "Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors." Eur J Cancer Clin Oncol 24 :675-679 .

61. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, Einhorn LH (1993 ): "Surgical salvage of chemorefractory germ cell tumors." J Clin Oncol 11 :324-329 .

62. Newlands ES, Bagshawe KD (1977 ): " Epipodophyllin derivative (VP16-213) in malignant teratomas and chorioncarcinomas." Lancet II :87 .

63. Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN, Giannone L, Greer J, Einhorn LH, Jansen J (1989 ): "Dose-intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation." J Clin Oncol 7 :932-939 .

60

64. Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, Loehrer PJ, Trump DL (1992 ): "High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol." J Clin Oncol 10 :558-563 .

65. Nichols CR, Roth BJ, Loehrer PJ, Williams SD, Einhorn LH (1994 ): "Salvage chemotherapy for recurrent germ cell cancer." Semin Oncol 21 :102-108 .

66. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998 ): "Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an eastern cooperative oncology group, southwest oncology group, and cancer and leukemia group B study." J Clin Oncol 16 :1287-1293 .

67. Pizzocaro G, Pasi M, Salvioni R, Zanoni F, Milani A, Piva L (1985 ): "Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer." Cancer 56 :2399-2403 .

68. Pont J, Holtl W, Weissbach L, Beyer J, Siegert W (1997 ): "Hochdosischemotherapie und Reinfusion von hämatopoetischen Stammzellen bei fortgeschrittenen Keimzelltumoren mit schlechter Prognose - Stand 1996." Urologe A 36 :561-564 .

69. Rick O, Beyer J, Kingreen D, Schwella N, Krusch A, Schleicher J, Kirsch A, Huhn D, Siegert W (1998 ): "High-dose chemotherapy in germ cell tumours: a large single centre experience." Eur J Cancer 34 :1883-1888 .

70. Rosti G, Albertazzi L, Salvioni R, Pizzocaro G, Cetto GL, Bassetto MA, Marangolo M (1992 ): "High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study." Ann Oncol 3 :809-812 .

71. Sachs L . Angewandte Statistik . Heidelberg : Springer-Verlag , 1992 .

72. Sandler A, Loehrer P: "Salvage therapy and autologous bone marrow transplantation" , in Horwich A (ed): Testicular cancer . 2 ed. London, Chapman and Hall Medical, 1996 , pp 307-318 .

73. Saxman SB, Nichols CR, Einhorn LH (1994 ): "Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience." J Clin Oncol 12 :1390-1393 .

74. Schwella N, Beyer J, Schwaner I, Heuft HG, Rick O, Huhn D, Serke S, Siegert W (1996 ): "Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer." J Clin Oncol 14 :1114-1121 .

61

75. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D (1994 ): "High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. " J Clin Oncol 12 :1223-1231 .

76. Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, Bowers CE, Kronmueller N, Niemeyer R, McIntyre W (1994 ): "Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit." J Clin Oncol 12 :661-670 .

77. Thadhani R, Pascual M, Bonventre JV (1996 ): "Acute renal failure." N Engl J Med 334 :1448-1460 .

78. To LB, Haylock DN, Simmons PJ, Juttner CA (1997 ): " The biology and clinical uses of blood stem cells." Blood 89 :2233-2258 .

79. Wheeler C, Loehrer PJ, Williams SD, Einhorn LH (1986 ): " Ifosfamide in refractory male germ cell tumors." J Clin Oncol 4 :28-34 .

80. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987 ): " Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastine or etoposide." N Engl J Med 316 :1435-1440 .

81. Williams SD (1992 ): "High dose therapy in germ cell tumors: when, what, and how much." Ann Oncol 3 :780-781 .

82. Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, Goldspiel B, Steinberg SM, Longo DL, Wittes RE (1992 ): "Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors." J Clin Oncol 10 :1712-1722 .

83. Wolff SN, Johnson DH, Hainsworth JD, Greco FA (1984 ): " High-dose VP-16-123 monotherapy for refractory germinal malignancies: a phase II study." J Clin Oncol 2 :271-274 .

84. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: WHO Offset Publication, 1979 .

85. World Medical Organization Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Amended by the 41st World Medical Assembly, Hong Kong , 1989 .

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.